Literature DB >> 29176264

Efficacy of Chondroitin Sulfate for Painful Knee Osteoarthritis: A One-Year, Randomized, Double-Blind, Multicenter Clinical Study in Japan.

Mitsuhiro Morita1, Kotaro Yamada2, Hideki Date1, Kazue Hayakawa1, Hidetomo Sakurai2, Harumoto Yamada1.   

Abstract

We explored the effects of chondroitin sulfate on knee osteoarthritis in a one-year, randomized, double-blind, dose-comparison study. Patients with painful, Kellgren-Lawrence grade 2-3, osteoarthritis of the knee were treated with oral chondroitin sulfate at a dose of either 260 mg/d (low-dose group, control group) or 1560 mg/d (high-dose group). Symptoms were evaluated by the Lequesne's index and visual analog scale for pain. We made subgroup analyses according to background symptom severity (Lequesne's index ≥8 or <8) in 73 patients. Serum level of cartilage oligomeric matrix protein and hyaluronic acid were also determined. In the subgroup with severe symptoms (Lequesne's index ≥8), the chondroitin sulfate dose of 1560 mg/d improved pain faster after 6 and 9 months' therapy. However, no dose-related effects were found on cartilage oligomeric matrix protein or hyaluronic acid levels. Chondroitin sulfate also had good tolerability. We conclude that chondroitin sulfate is useful for pain control in knee osteoarthritis.

Entities:  

Keywords:  chondroitin sulfate; clinical trial; pain-management; randomized controlled trial

Mesh:

Substances:

Year:  2017        PMID: 29176264     DOI: 10.1248/bpb.b17-00556

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  1 in total

1.  Effects of oral treatment with chondroitin sulfate and glucosamine in an experimental model of metacarpophalangeal osteoarthritis in horses.

Authors:  Ana Lucia Miluzzi Yamada; Cynthia do Prado Vendruscolo; Marília Ferrari Marsiglia; Eric Danilo Pauls Sotelo; Fernanda Rodrigues Agreste; Sarah Raphaela Torquato Seidel; Joice Fülber; Raquel Yvonne Arantes Baccarin; Luis Claudio Lopes Correia da Silva
Journal:  BMC Vet Res       Date:  2022-06-09       Impact factor: 2.792

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.